{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:01:30Z","timestamp":1771891290141,"version":"3.50.1"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Immunol Res"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s12026-020-09154-4","type":"journal-article","created":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T18:03:47Z","timestamp":1601575427000},"page":"315-324","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Recent advances, approaches and challenges in targeting pathways for potential COVID-19 vaccines development"],"prefix":"10.1007","volume":"68","author":[{"given":"Daniela","family":"Calina","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chandan","family":"Sarkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreea Letitia","family":"Arsene","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bahare","family":"Salehi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8162-5955","authenticated-orcid":false,"given":"Anca Oana","family":"Docea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milon","family":"Mondal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad Torequl","family":"Islam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alireza","family":"Zali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javad","family":"Sharifi-Rad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,10,1]]},"reference":[{"issue":"6","key":"9154_CR1","first-page":"1631","volume":"45","author":"AO Docea","year":"2020","unstructured":"Docea AO, Tsatsakis A, Albulescu D, Cristea O, Zlatian O, Vinceti M, et al. A new threat from an old enemy: re-emergence of coronavirus. Int J Mol Med. 2020;45(6):1631\u201343.","journal-title":"Int J Mol Med"},{"issue":"10223","key":"9154_CR2","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0140-6736(20)30211-7","volume":"395","author":"N Chen","year":"2020","unstructured":"Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507\u201313.","journal-title":"Lancet"},{"issue":"1","key":"9154_CR3","first-page":"20","volume":"22","author":"M Goumenou","year":"2020","unstructured":"Goumenou M, Sarigiannis D, Tsatsakis A, Anesti O, Docea AO, Petrakis D, et al. COVID-19 in Northern Italy: an integrative overview of factors possibly influencing the sharp increase of the outbreak. Mol Med Rep. 2020;22(1):20\u201332.","journal-title":"Mol Med Rep"},{"key":"9154_CR4","doi-asserted-by":"crossref","first-page":"111418","DOI":"10.1016\/j.fct.2020.111418","volume":"141","author":"A Tsatsakis","year":"2020","unstructured":"Tsatsakis A, Petrakis D, Nikolouzakis TK, Docea AO, Calina D, Vinceti M, et al. COVID-19, an opportunity to reevaluate the correlation between long-term effects of anthropogenic pollutants on viral epidemic\/pandemic events and prevalence. Food Chem Toxicol. 2020;141:111418.","journal-title":"Food Chem Toxicol"},{"key":"9154_CR5","doi-asserted-by":"publisher","unstructured":"Adams ER, Augustin Y, Byrne RL, et al. Rapid development of COVID-19 rapid diagnostics for low resource settings: accelerating delivery through transparency, responsiveness, and open collaboration. medRxiv; 2020. https:\/\/doi.org\/10.1101\/2020.04.29.20082099.","DOI":"10.1101\/2020.04.29.20082099"},{"issue":"12","key":"9154_CR6","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1111\/j.1469-0691.2004.01009.x","volume":"10","author":"P-R Hsueh","year":"2004","unstructured":"Hsueh P-R, Huang LM, Chen PJ, Kao CL, Yang PC. Chronological evolution of IgM, IgA, IgG and neutralisation antibodies after infection with SARS-associated coronavirus. Clin Microbiol Infect. 2004;10(12):1062\u20136.","journal-title":"Clin Microbiol Infect"},{"key":"9154_CR7","doi-asserted-by":"crossref","first-page":"104468","DOI":"10.1016\/j.jcv.2020.104468","volume":"129","author":"KG Beavis","year":"2020","unstructured":"Beavis KG, Matushek SM, Abeleda APF, Bethel C, Hunt C, Gillen S, et al. Evaluation of the EUROIMMUN anti-SARS-CoV-2 ELISA assay for detection of IgA and IgG antibodies. J Clin Virol. 2020;129:104468.","journal-title":"J Clin Virol"},{"key":"9154_CR8","doi-asserted-by":"crossref","first-page":"104521","DOI":"10.1016\/j.jcv.2020.104521","volume":"129","author":"A Ayouba","year":"2020","unstructured":"Ayouba A, Thaurignac G, Morquin D, Tuaillon E, Raulino R, Nkuba A, et al. Multiplex detection and dynamics of IgG antibodies to SARS-CoV2 and the highly pathogenic human coronaviruses SARS-CoV and MERS-CoV. J Clin Virol. 2020;129:104521.","journal-title":"J Clin Virol"},{"issue":"7819","key":"9154_CR9","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/s41586-020-2380-z","volume":"584","author":"B Ju","year":"2020","unstructured":"Ju B, Zhang Q, Ge J, Wang R, Sun J, Ge X, et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. 2020;584(7819):115\u20139. https:\/\/doi.org\/10.1038\/s41586-020-2380-z.","journal-title":"Nature"},{"issue":"1","key":"9154_CR10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-019-13993-7","volume":"11","author":"C Wang","year":"2020","unstructured":"Wang C, et al. A human monoclonal antibody blocking SARS-CoV-2 infection. Nat Commun. 2020;11(1):1\u20136.","journal-title":"Nat Commun"},{"key":"9154_CR11","doi-asserted-by":"publisher","unstructured":"OKBA NM, Muller MA, Li W, et al. SARS-CoV-2 specific antibody responses in COVID-19 patients. medRxiv; 2020. https:\/\/doi.org\/10.1101\/2020.03.18.20038059.","DOI":"10.1101\/2020.03.18.20038059"},{"key":"9154_CR12","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.it.2020.04.001","volume":"41","author":"JS Tsang","year":"2020","unstructured":"Tsang JS, Doba\u00f1o C, VanDamme P, Moncunill G, Marchant A, Othman RB, et al. Improving vaccine-induced immunity: can Baseline Predict Outcome? Trends Immunol. 2020;41:457\u201365.","journal-title":"Trends Immunol"},{"key":"9154_CR13","doi-asserted-by":"publisher","unstructured":"Jiang S, Hillyer C, Du L. Neutralizing antibodies against SARS-CoV-2 and other human Coronaviruses. Trends Immunol. 2020;41(5):355\u20139. https:\/\/doi.org\/10.1016\/j.it.2020.03.007.","DOI":"10.1016\/j.it.2020.03.007"},{"issue":"21","key":"9154_CR14","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1056\/NEJMp2005630","volume":"382","author":"N Lurie","year":"2020","unstructured":"Lurie N, Saville M, Hatchett R, Halton J. Developing Covid-19 vaccines at pandemic speed. N Engl J Med. 2020;382(21):1969\u201373.","journal-title":"N Engl J Med"},{"key":"9154_CR15","doi-asserted-by":"crossref","first-page":"110049","DOI":"10.1016\/j.mehy.2020.110049","volume":"144","author":"A Yaqinuddin","year":"2020","unstructured":"Yaqinuddin A. Cross-immunity between respiratory coronaviruses may limit COVID-19 fatalities. Med Hypotheses. 2020;144:110049.","journal-title":"Med Hypotheses"},{"key":"9154_CR16","doi-asserted-by":"publisher","unstructured":"Caturegli G, Materi J, Howard BM, Caturegli P. Clinical validity of serum antibodies to SARS-CoV-2: a case-control study. Ann Intern Med. 2020;6:M20\u20132889. https:\/\/doi.org\/10.7326\/M20-2889.","DOI":"10.7326\/M20-2889"},{"issue":"2","key":"9154_CR17","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.micinf.2020.02.006","volume":"22","author":"JA Tetro","year":"2020","unstructured":"Tetro JA. Is COVID-19 receiving ADE from other coronaviruses? Microbes Infect. 2020;22(2):72\u20133.","journal-title":"Microbes Infect"},{"issue":"1","key":"9154_CR18","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3892\/ijmm.2020.4596","volume":"46","author":"D Calina","year":"2020","unstructured":"Calina D, Docea A, Petrakis D, Egorov A, Ishmukhametov A, Gabibov A, et al. Towards effective COVID-19 vaccines: updates, perspectives and challenges. Int J Mol Med. 2020;46(1):3\u201316.","journal-title":"Int J Mol Med"},{"issue":"12","key":"9154_CR19","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1016\/j.vaccine.2011.11.053","volume":"30","author":"L Tomljenovic","year":"2012","unstructured":"Tomljenovic L, Shaw CA. \u201cOne-size fits all\u201c? Vaccine. 2012;30(12):2040. https:\/\/doi.org\/10.1016\/j.vaccine.2011.11.053.","journal-title":"Vaccine."},{"issue":"6493","key":"9154_CR20","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1126\/science.abb5793","volume":"368","author":"SM Kissler","year":"2020","unstructured":"Kissler SM, Tedijanto C, Goldstein E, Grad YH, Lipsitch M. Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period. Science. 2020;368(6493):860\u20138.","journal-title":"Science"},{"key":"9154_CR21","doi-asserted-by":"publisher","unstructured":"Grifoni A, Weiskopf D, Ramirez SI, et al. Targets of T cell responses to SARS-CoV-2 Coronavirus in humans with COVID-19 disease and unexposed individuals. Cell. 2020;181(7):1489\u2013501.e15. https:\/\/doi.org\/10.1016\/j.cell.2020.05.015.","DOI":"10.1016\/j.cell.2020.05.015"},{"issue":"1","key":"9154_CR22","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3892\/ijmm.2020.4596","volume":"46","author":"D Calina","year":"2020","unstructured":"Calina D, Docea A, Petrakis D, Egorov A, Ishmukhametov A, Gabibov A, et al. Towards effective COVID-19 vaccines: updates, perspectives and challenges (Review). Int J Mol Med. 2020;46(1):3\u201316.","journal-title":"Int J Mol Med"},{"issue":"1","key":"9154_CR23","first-page":"21","volume":"33","author":"JM McAnulty","year":"2009","unstructured":"McAnulty JM, et al. Vaccine failures and vaccine effectiveness in children during measles outbreaks in New South Wales, March-May 2006. Commun Dis Intell Q Rep. 2009;33(1):21.","journal-title":"Commun Dis Intell Q Rep"},{"issue":"1","key":"9154_CR24","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1586\/erv.12.134","volume":"12","author":"IH Haralambieva","year":"2013","unstructured":"Haralambieva IH, Ovsyannikova IG, Pankratz VS, Kennedy RB, Jacobson RM, Poland GA. The genetic basis for interindividual immune response variation to measles vaccine: new understanding and new vaccine approaches. Expert Rev Vaccines. 2013;12(1):57\u201370.","journal-title":"Expert Rev Vaccines"},{"key":"9154_CR25","unstructured":"Kudrat-E-Zahan M, et al. A perspective on emerging therapeutic interventions for COVID-19."},{"issue":"1","key":"9154_CR26","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1080\/21645515.2015.1093263","volume":"12","author":"U Wiedermann","year":"2016","unstructured":"Wiedermann U, Garner-Spitzer E, Wagner A. Primary vaccine failure to routine vaccines: why and what to do? Hum Vaccin Immunother. 2016;12(1):239\u201343.","journal-title":"Hum Vaccin Immunother"},{"issue":"1","key":"9154_CR27","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S1473-3099(11)70295-X","volume":"12","author":"MT Osterholm","year":"2012","unstructured":"Osterholm MT, Kelley NS, Sommer A, Belongia EA. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis. 2012;12(1):36\u201344.","journal-title":"Lancet Infect Dis"},{"key":"9154_CR28","doi-asserted-by":"publisher","unstructured":"Wu F, et al. Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications. medRxiv. 2020; 2020\u2013033020047365. https:\/\/doi.org\/10.1101\/2020.03.30.20047365. Accessed 2020-04-29.","DOI":"10.1101\/2020.03.30.20047365"},{"issue":"15","key":"9154_CR29","doi-asserted-by":"crossref","first-page":"8218","DOI":"10.1073\/pnas.2005456117","volume":"117","author":"L Peeples","year":"2020","unstructured":"Peeples L. News feature: avoiding pitfalls in the pursuit of a COVID-19 vaccine. Proc Natl Acad Sci. 2020;117(15):8218\u201321.","journal-title":"Proc Natl Acad Sci"},{"issue":"7","key":"9154_CR30","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1086\/528993","volume":"197","author":"I Davidkin","year":"2008","unstructured":"Davidkin I, Jokinen S, Broman M, Leinikki P, Peltola H. Persistence of measles, mumps, and rubella antibodies in an MMR-vaccinated cohort: a 20-year follow-up. J Infect Dis. 2008;197(7):950\u20136.","journal-title":"J Infect Dis"},{"key":"9154_CR31","unstructured":"National Academies of Sciences, E. and Medicine, Integrating clinical research into epidemic response: the Ebola experience. National Academies Press; 2017."},{"issue":"10069","key":"9154_CR32","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/S0140-6736(16)32617-4","volume":"389","author":"F-C Zhu","year":"2017","unstructured":"Zhu F-C, Wurie AH, Hou LH, Liang Q, Li YH, Russell JBW, et al. Safety and immunogenicity of a recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in Sierra Leone: a single-centre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2017;389(10069):621\u20138.","journal-title":"Lancet"},{"issue":"2","key":"9154_CR33","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1017\/S0950268800048019","volume":"105","author":"KA Callow","year":"1990","unstructured":"Callow KA, Parry HF, Sergeant M, Tyrrell DAJ. The time course of the immune response to experimental coronavirus infection of man. Epidemiol Infect. 1990;105(2):435\u201346.","journal-title":"Epidemiol Infect"},{"issue":"11","key":"9154_CR34","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1056\/NEJMc070348","volume":"357","author":"W-C Cao","year":"2007","unstructured":"Cao W-C, Liu W, Zhang PH, Zhang F, Richardus JH. Disappearance of antibodies to SARS-associated coronavirus after recovery. N Engl J Med. 2007;357(11):1162\u20133.","journal-title":"N Engl J Med"},{"issue":"10","key":"9154_CR35","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.3201\/eid1310.070576","volume":"13","author":"LP Wu","year":"2007","unstructured":"Wu LP, Wang NC, Chang YH, Tian XY, Na DY, Zhang LY, et al. Duration of antibody responses after severe acute respiratory syndrome. Emerg Infect Dis. 2007;13(10):1562\u20134.","journal-title":"Emerg Infect Dis"},{"issue":"10","key":"9154_CR36","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.3201\/eid2210.160706","volume":"22","author":"DC Payne","year":"2016","unstructured":"Payne DC, Iblan I, Rha B, Alqasrawi S, Haddadin A, al Nsour M, et al. Persistence of antibodies against Middle East respiratory syndrome coronavirus. Emerg Infect Dis. 2016;22(10):1824\u20136.","journal-title":"Emerg Infect Dis"},{"key":"9154_CR37","doi-asserted-by":"publisher","unstructured":"Poutanen SM. Human Coronaviruses. Principles and Practice of Pediatric Infectious Diseases. 2018;1148\u201352.e3. https:\/\/doi.org\/10.1016\/B978-0-323-40181-4.00222-X.","DOI":"10.1016\/B978-0-323-40181-4.00222-X"},{"issue":"6","key":"9154_CR38","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.3201\/eid2206.160010","volume":"22","author":"AN Alshukairi","year":"2016","unstructured":"Alshukairi AN, et al. Antibody response and disease severity in healthcare worker MERS survivors. Emerg Infect Dis. 2016;22(6):1113\u20135.","journal-title":"Emerg Infect Dis"},{"key":"9154_CR39","unstructured":"Organization, W.H., DRAFT landscape of COVID-19 candidate vaccines. World. 2020."},{"issue":"18","key":"9154_CR40","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1001\/jama.2017.15033","volume":"318","author":"HD Marston","year":"2017","unstructured":"Marston HD, Paules CI, Fauci AS. The critical role of biomedical research in pandemic preparedness. JAMA. 2017;318(18):1757\u20138.","journal-title":"JAMA"},{"issue":"4","key":"9154_CR41","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","volume":"17","author":"N Pardi","year":"2018","unstructured":"Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines\u2014a new era in vaccinology. Nat Rev Drug Discov. 2018;17(4):261\u201379.","journal-title":"Nat Rev Drug Discov"},{"key":"9154_CR42","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.3389\/fimmu.2018.01963","volume":"9","author":"S Rauch","year":"2018","unstructured":"Rauch S, Jasny E, Schmidt KE, Petsch B. New vaccine technologies to combat outbreak situations. Front Immunol. 2018;9:1963.","journal-title":"Front Immunol"},{"issue":"1","key":"9154_CR43","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1038\/s41598-018-21630-4","volume":"8","author":"CM Bliss","year":"2018","unstructured":"Bliss CM, Bowyer G, Anagnostou NA, Havelock T, Snudden CM, Davies H, et al. Assessment of novel vaccination regimens using viral vectored liver stage malaria vaccines encoding ME-TRAP. Sci Rep. 2018;8(1):3390.","journal-title":"Sci Rep"},{"issue":"17","key":"9154_CR44","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1056\/NEJMoa1411627","volume":"374","author":"K Ewer","year":"2016","unstructured":"Ewer K, Rampling T, Venkatraman N, Bowyer G, Wright D, Lambe T, et al. A monovalent chimpanzee adenovirus Ebola vaccine boosted with MVA. N Engl J Med. 2016;374(17):1635\u201346.","journal-title":"N Engl J Med"},{"issue":"7805","key":"9154_CR45","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/d41586-020-01221-y","volume":"580","author":"E Callaway","year":"2020","unstructured":"Callaway E. The race for coronavirus vaccines: a graphical guide. Nature. 2020;580(7805):576\u20137.","journal-title":"Nature"},{"issue":"4","key":"9154_CR46","first-page":"593","volume":"36","author":"L Yang","year":"2020","unstructured":"Yang L, Tian D, Liu W. Strategies for vaccine development of COVID-19. Sheng Wu Gong Cheng Xue Bao. 2020;36(4):593.","journal-title":"Sheng Wu Gong Cheng Xue Bao"},{"key":"9154_CR47","doi-asserted-by":"publisher","unstructured":"Khuroo MS, Khuroo M, Khuroo MS, Sofi AA, Khuroo NS. COVID-19 Vaccines: A Race Against Time in the Middle of Death and Devastation! J Clin Exp Hepatol. 2020. https:\/\/doi.org\/10.1016\/j.jceh.2020.06.003.","DOI":"10.1016\/j.jceh.2020.06.003"},{"issue":"5","key":"9154_CR48","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.biologicals.2014.07.003","volume":"42","author":"J Petricciani","year":"2014","unstructured":"Petricciani J, Sheets R, Griffiths E, Knezevic I. Adventitious agents in viral vaccines: lessons learned from 4 case studies. Biologicals. 2014;42(5):223\u201336.","journal-title":"Biologicals"},{"key":"9154_CR49","unstructured":"Agency, E.M., Guideline on quality, non-clinical and clinical requirements for investigational advanced therapy medicinal products in clinical trials. 2020."},{"issue":"1","key":"9154_CR50","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.biologicals.2010.12.001","volume":"39","author":"F De Mattia","year":"2011","unstructured":"De Mattia F, et al. The consistency approach for quality control of vaccines\u2013a strategy to improve quality control and implement 3Rs. Biologicals. 2011;39(1):59\u201365.","journal-title":"Biologicals"},{"issue":"9","key":"9154_CR51","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.celrep.2019.10.105","volume":"29","author":"J Powlson","year":"2019","unstructured":"Powlson J, et al. Characterization of antigenic MHC-class-I-restricted t cell epitopes in the glycoprotein of ebolavirus. Cell Rep. 2019;29(9):2537\u20132545.e3.","journal-title":"Cell Rep"},{"issue":"4","key":"9154_CR52","doi-asserted-by":"crossref","first-page":"261","DOI":"10.14573\/altex.1509081","volume":"32","author":"M Daneshian","year":"2015","unstructured":"Daneshian M, Busquet F, Hartung T, Leist M. Animal use for science in Europe. Alternatives to animal experimentation. ALTEX. 2015;32(4):261\u201374.","journal-title":"ALTEX"},{"issue":"3","key":"9154_CR53","doi-asserted-by":"crossref","first-page":"e57755","DOI":"10.1371\/journal.pone.0057755","volume":"8","author":"ES Pronker","year":"2013","unstructured":"Pronker ES, Weenen TC, Commandeur H, Claassen EHJHM, Osterhaus ADME. Risk in vaccine research and development quantified. PLoS One. 2013;8(3):e57755.","journal-title":"PLoS One"},{"issue":"5","key":"9154_CR54","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/nbt0596-591","volume":"14","author":"M-M Struck","year":"1996","unstructured":"Struck M-M. Vaccine R&D success rates and development times. Nat Biotechnol. 1996;14(5):591\u20133.","journal-title":"Nat Biotechnol"},{"key":"9154_CR55","unstructured":"FDA, Investigational new drug (IND) Application. 2020."},{"key":"9154_CR56","unstructured":"Agency, E.M., Clinical Trial Regulation. 2019."},{"issue":"6","key":"9154_CR57","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.31925\/farmacia.2019.6.12","volume":"67","author":"NB Bulik","year":"2019","unstructured":"Bulik NB, et al. Reactogenicity and medically attended adverse events following hexavalent vaccination: an observational prospective study. Farmacia. 2019;67(6):1018\u201324.","journal-title":"Farmacia"},{"issue":"2","key":"9154_CR58","doi-asserted-by":"crossref","first-page":"219","DOI":"10.31925\/farmacia.2020.2.5","volume":"68","author":"C Bucsa","year":"2020","unstructured":"Bucsa C, et al. Adverse events following measles-mumps-rubella vaccination. A prospective observational study. Farmacia. 2020;68(2):219\u201324.","journal-title":"Farmacia"},{"key":"9154_CR59","doi-asserted-by":"publisher","unstructured":"Calina D, Hartung T, Docea AO, et al. COVID-19 vaccines: ethical framework concerning human challenge studies. DARU J Pharm Sci 2020;1\u20136. https:\/\/doi.org\/10.1007\/s40199-020-00371-8.","DOI":"10.1007\/s40199-020-00371-8"},{"issue":"5","key":"9154_CR60","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/d41573-020-00073-5","volume":"19","author":"TT Le","year":"2020","unstructured":"Le TT, et al. The COVID-19 vaccine development landscape. Nat Rev Drug Discov. 2020;19(5):305\u20136.","journal-title":"Nat Rev Drug Discov"},{"key":"9154_CR61","unstructured":"Medicine, N.L.o., Safety and immunogenicity study of 2019-nCoV vaccine (mRNA-1273) for prophylaxis SARS CoV-2 infection (COVID-19). 2020."},{"key":"9154_CR62","unstructured":"Medicine, N.L.o., Safety, tolerability and immunogenicity of INO-4800 for COVID-19 in healthy volunteers. 2020."},{"key":"9154_CR63","unstructured":"Medicine, N.L.o., Phase I clinical trial of a COVID-19 vaccine in 18-60 healthy adults (CTCOVID-19). 2020."},{"key":"9154_CR64","unstructured":"Medicine, N.L.o., Immunity and safety of Covid-19 synthetic minigene vaccine. 2020."},{"issue":"2","key":"9154_CR65","doi-asserted-by":"crossref","first-page":"185","DOI":"10.31925\/farmacia.2020.2.1","volume":"68","author":"AL Arsene","year":"2020","unstructured":"Arsene AL, et al. A new era for the therapeutic management of the ongoing COVID-19 pandemic. Farmacia. 2020;68(2):185\u201396.","journal-title":"Farmacia"}],"container-title":["Immunologic Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12026-020-09154-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12026-020-09154-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12026-020-09154-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:39:51Z","timestamp":1633048791000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12026-020-09154-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,1]]},"references-count":65,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["9154"],"URL":"https:\/\/doi.org\/10.1007\/s12026-020-09154-4","relation":{},"ISSN":["0257-277X","1559-0755"],"issn-type":[{"value":"0257-277X","type":"print"},{"value":"1559-0755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,1]]},"assertion":[{"value":"2 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Not applicable","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}